admin – Page 4244 – Get News Story

Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment

Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are – Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.
In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing the investigational treatment Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced a positive result from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b CORAL trial in IPF patients with chronic cough. The outcome indicates that no adjustments are needed to the current sample size for the trial (N=160).
In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.
In May 2024, Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced topline results from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital. The trial evaluated changes in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a condition marked by excessive collagen buildup in the lungs.
In March 2024, US-based Seyltx finalized an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common and distressing symptom of this chronic lung disease. IPF causes scarring and thickening of the lung tissue, leading to breathing difficulties and persistent dry, non-productive cough. The exact cause of cough in IPF is not fully understood, but it is believed to result from the irritation caused by the fibrosis (scarring) of the lung tissue, which can trigger the cough reflex. This cough is often persistent, worsening over time, and can significantly impact a patient’s quality of life. Treatment typically focuses on managing symptoms and slowing the progression of IPF.

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

Orvepitant Maleate: NeRRe Therapeutics
Haduvio (nalbuphine ER): Trevi Therapeutics
ME-015 (Suplatast Tosilate): Melius Pharma AB
BI 1839100: Boehringer Ingelheim

Cough in Idiopathic Pulmonary Fibrosis Route of Administration

Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Cough in Idiopathic Pulmonary Fibrosis Molecule Type

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type
Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type
Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are – Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

Coverage: Global
Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others
Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others
Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction

2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary

3. Cough in Idiopathic Pulmonary Fibrosis Overview

4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cough in Idiopathic Pulmonary Fibrosis Key Companies

14. Cough in Idiopathic Pulmonary Fibrosis Key Products

15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi

Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlight | Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Rhinosinusitis with Nasal Polyps pipeline constitutes 8+ key companies continuously working towards developing 10+ Chronic Rhinosinusitis with Nasal Polyps treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Rhinosinusitis with Nasal Polyps Market.

The Chronic Rhinosinusitis with Nasal Polyps Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report:

Companies across the globe are diligently working toward developing novel Chronic Rhinosinusitis with Nasal Polyps treatment therapies with a considerable amount of success over the years.
Chronic Rhinosinusitis with Nasal Polyps companies working in the treatment market are AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others, are developing therapies for the Chronic Rhinosinusitis with Nasal Polyps treatment

Emerging Chronic Rhinosinusitis with Nasal Polyps therapies in the different phases of clinical trials are- NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others are expected to have a significant impact on the Chronic Rhinosinusitis with Nasal Polyps market in the coming years.
In November 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
In May 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Chronic Rhinosinusitis with Nasal Polyps Overview

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a long-lasting condition characterized by inflammation of the sinuses and nasal passages, often accompanied by the growth of benign, non-cancerous polyps (growths of tissue) inside the nasal cavity. It typically causes symptoms such as nasal congestion, loss of smell, facial pain or pressure, and nasal discharge. This condition can lead to significant discomfort and affect quality of life. The exact cause of CRSwNP is not fully understood, but it is often associated with factors such as allergies, asthma, and immune system dysfunction. Treatment may include medications such as nasal corticosteroids, oral steroids, and in some cases, surgery to remove the polyps.

Get a Free Sample PDF Report to know more about Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight?

Emerging Chronic Rhinosinusitis with Nasal Polyps Drugs Under Different Phases of Clinical Development Include:

NUCALA (mepolizumab): GlaxoSmithKline
TEZSPIRE (tezepelumab): AstraZeneca/Amgen
FASENRA (benralizumab): AstraZeneca
Tezepelumab: AstraZeneca/Amgen
CM310: Keymed Biosciences
GSK3511294 (depemokimab): GlaxoSmithKline
Omalizumab: Genentech, Inc
Xolair: Novartis
Verekitug (UPB-101): Upstream Bio Inc.
Dupilumab SAR231893: Regeneron Pharmaceuticals
GR1802 injection: Genrix (Shanghai) Biopharmaceutical
SHR-1905 Injection: Guangdong Hengrui Pharmaceutical
CM310: Keymed Biosciences Co.Ltd

Chronic Rhinosinusitis with Nasal Polyps Route of Administration

Chronic Rhinosinusitis with Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Chronic Rhinosinusitis with Nasal Polyps Molecule Type

Chronic Rhinosinusitis with Nasal Polyps Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics Assessment

Chronic Rhinosinusitis with Nasal Polyps Assessment by Product Type
Chronic Rhinosinusitis with Nasal Polyps By Stage and Product Type
Chronic Rhinosinusitis with Nasal Polyps Assessment by Route of Administration
Chronic Rhinosinusitis with Nasal Polyps By Stage and Route of Administration
Chronic Rhinosinusitis with Nasal Polyps Assessment by Molecule Type
Chronic Rhinosinusitis with Nasal Polyps by Stage and Molecule Type

DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Chronic Rhinosinusitis with Nasal Polyps product details are provided in the report. Download the Chronic Rhinosinusitis with Nasal Polyps pipeline report to learn more about the emerging Chronic Rhinosinusitis with Nasal Polyps therapies

Some of the key companies in the Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market include:

Key companies developing therapies for Chronic Rhinosinusitis with Nasal Polyps are – Keymed Biosciences Co.Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others

Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis:

The Chronic Rhinosinusitis with Nasal Polyps pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Rhinosinusitis with Nasal Polyps with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Rhinosinusitis with Nasal Polyps Treatment.
Chronic Rhinosinusitis with Nasal Polyps key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Rhinosinusitis with Nasal Polyps Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Rhinosinusitis with Nasal Polyps market.

Download Sample PDF Report to know more about Chronic Rhinosinusitis with Nasal Polyps drugs and therapies

Chronic Rhinosinusitis with Nasal Polyps Pipeline Market Drivers

Increasing Prevalence, Rising Awareness, Advances in Treatment Options, Growing Focus on Biologics, Unmet Medical Needs, Favorable Regulatory Support, Increased Investment in R&D, are some of the important factors that are fueling the Chronic Rhinosinusitis with Nasal Polyps Market.

Chronic Rhinosinusitis with Nasal Polyps Pipeline Market Barriers

However, High Treatment Costs, Long Development Timelines, Side Effects of Existing Therapies, Limited Treatment Efficacy, Regulatory Hurdles, Complexity of Disease Pathophysiology, and other factors are creating obstacles in the Chronic Rhinosinusitis with Nasal Polyps Market growth.

Scope of Chronic Rhinosinusitis with Nasal Polyps Pipeline Drug Insight

Coverage: Global
Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
Key Chronic Rhinosinusitis with Nasal Polyps Therapies: NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and Chronic Rhinosinusitis with Nasal Polyps emerging therapies
Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Chronic Rhinosinusitis with Nasal Polyps market drivers and Chronic Rhinosinusitis with Nasal Polyps market barriers

Request for Sample PDF Report for Chronic Rhinosinusitis with Nasal Polyps Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Rhinosinusitis with Nasal Polyps Report Introduction

2. Chronic Rhinosinusitis with Nasal Polyps Executive Summary

3. Chronic Rhinosinusitis with Nasal Polyps Overview

4. Chronic Rhinosinusitis with Nasal Polyps- Analytical Perspective In-depth Commercial Assessment

5. Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics

6. Chronic Rhinosinusitis with Nasal Polyps Late Stage Products (Phase II/III)

7. Chronic Rhinosinusitis with Nasal Polyps Mid Stage Products (Phase II)

8. Chronic Rhinosinusitis with Nasal Polyps Early Stage Products (Phase I)

9. Chronic Rhinosinusitis with Nasal Polyps Preclinical Stage Products

10. Chronic Rhinosinusitis with Nasal Polyps Therapeutics Assessment

11. Chronic Rhinosinusitis with Nasal Polyps Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Rhinosinusitis with Nasal Polyps Key Companies

14. Chronic Rhinosinusitis with Nasal Polyps Key Products

15. Chronic Rhinosinusitis with Nasal Polyps Unmet Needs

16 . Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers

17. Chronic Rhinosinusitis with Nasal Polyps Future Perspectives and Conclusion

18. Chronic Rhinosinusitis with Nasal Polyps Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlight | Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream

TLC Private Home Care Expands 24-Hour Live-In Nursing Services in Cape Cod & Southeastern, MA

Providing peace of mind and high-quality care for seniors and their families.

Cape Cod & Southeastern, MA – TLC Private Home Care is proud to announce the continued offering of its premier 24-hour live-in nursing services across Cape Cod and Southeastern Massachusetts. This service recognizes the critical need for round-the-clock support for seniors and ensures families can access personalized, high-quality care tailored to their loved ones’ needs.

“Our mission at TLC Private Home Care has always been to provide compassionate, comprehensive care that helps seniors maintain their dignity and independence at home,” said Steve Cicchese, owner of TLC Private Home Care. “Our 24-hour live-in nursing services offer families peace of mind, knowing their loved ones receive exceptional care in a familiar and comforting environment. We are committed to supporting the well-being of our community’s seniors and their families.”

The advantages of 24-hour live-in nursing care are profound, particularly for seniors who require ongoing medical attention and support. With a professional caregiver permanently on-site, families can rest assured that their loved ones are constantly monitored and cared for. This reduces the risks associated with emergencies, such as falls, sudden illness, or medication errors, providing unparalleled peace of mind.

Round-the-clock care also offers seniors the comfort and stability of remaining in their own homes. By avoiding relocation to a nursing home or assisted living facility, seniors can maintain their independence and preserve the routines and environments they cherish. This familiar setting often contributes to emotional well-being and a higher quality of life, especially for individuals with cognitive challenges or chronic conditions.

In addition to meeting physical health needs, 24-hour nursing care provides invaluable companionship and emotional support. Caregivers build meaningful relationships with their clients, alleviating feelings of loneliness and isolation. This personalized attention fosters trust and a sense of security, ensuring that seniors feel valued and cared for.

TLC Private Home Care’s 24-hour nurse care services address the unique challenges of seniors, including those living with chronic conditions, cognitive impairments, or disabilities. By offering live-in care, the company helps reduce hospitalizations and fosters a higher quality of life, emphasizing safety, independence, and emotional well-being.

For more information about the company and its 24-hour live-in nursing care in Cape Cod and Southeastern, MA, please visit its website at https://tlcprivate.com

About TLC Private Home Care:

TLC Private Home Care is a leading provider of personalized in-home care services in Cape Cod and Southeastern Massachusetts. Dedicated to enhancing the quality of life for seniors, the company offers a range of services tailored to individual needs, from live-in nursing care to daily assistance. Committed to compassion, professionalism, and excellence, TLC Private Home Care is a trusted partner for families seeking comprehensive home care solutions.

Media Contact
Company Name: TLC Private Home Care
Email: Send Email
Phone: (774) 310-3876
Address:25 Main Street, Buzzards bay
City: Bourne
State: Massachusetts 02532-3106
Country: United States
Website: https://tlcprivate.com/buzzards-bay-and-barnstable-county-ma/

Therma Bright Inc. (OTC: TBRIF) Expands in $6.72 Billion Compression Market

In an aging world where healthcare costs are rising, the demand for cost-effective, non-invasive treatments is skyrocketing. One sector seeing a surge in interest is compression therapy, a market projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033. Traditionally dominated by compression stockings and bulky pneumatic devices, the space is undergoing a technological shift toward portable, user-friendly solutions—opening the door for companies developing next-generation devices.

One under-the-radar player making moves in this space is Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM) (FSE: JNX). The company’s Venowave VW5, an FDA-cleared, battery-powered compression device, has been gaining traction in the U.S. market, especially following recent reimbursement approvals from Medicare and private insurers. With a growing distribution network, strong early sales, and a huge addressable market, Therma Bright is quickly positioning itself as a compelling small-cap investment in a sector experiencing major tailwinds.

With reimbursement momentum building and major distribution deals already in place, is Therma Bright an overlooked gem in the booming compression therapy industry? Let’s take a closer look at the opportunity.

Therma Bright Inc.: Advancing Medical Innovation with Venowave VW5

Therma Bright Inc. is a developer and investment partner in advanced diagnostic and medical device technologies. The company focuses on delivering high-quality, innovative healthcare solutions to both consumers and medical professionals.

Milestone Achievement: HCPCS Code Reimbursement Secured

Therma Bright and its nationwide U.S. distribution partners have successfully secured Medicare and Medicaid HCPCS Level II code reimbursements within just 60 days. Since October 1, 2024, over 110 Venowave VW5 units have been deployed across the U.S. in pilot tests, with 25 units already receiving full reimbursement through commercial health networks and federal healthcare programs. The remaining 85 units are anticipated to follow suit soon.

Given these strong results, the company has initiated discussions on scaling sales, optimizing delivery logistics, and ramping up manufacturing with its distribution partners.

“Our U.S. national distributors are highly impressed with the speed of CMS reimbursements for the Venowave VW5,” said Rob Fia, CEO of Therma Bright. “Typically, brand-new HCPCS Level II codes require more time to process, but our code has been efficiently handled within 60 days. This sets a strong precedent for even faster reimbursements in the future and supports our commercialization efforts.”

Expanding U.S. Distribution with DME Authority

Therma Bright has signed a Letter of Intent (LOI) with DME Authority, a Nashville-based distributor, to significantly expand Venowave’s reach. Under this agreement, DME Authority will establish at least three comprehensive distribution agreements, requiring an initial inventory purchase of $2 million. Collectively, these partners will commit to purchasing $6 million worth of Venowave VW5 units within the first six months of 2025, with an equal commitment for Q3 and Q4.

DME Authority will also acquire Therma Bright’s remaining in-stock inventory as part of this agreement, ensuring seamless market expansion.

“Our strategy to secure Venowave’s HCPCS code was crucial, and the timing couldn’t be better,” said Erick Gosse, CEO of DME Authority. “Medicare patients have lacked a mobile mechanical compression solution—Venowave now fills that gap effectively.”

Venowave VW5

The Venowave VW5 is a compact, battery-operated peristaltic pump designed to improve vascular and lymphatic flow in the lower limbs. It qualifies for Medicare and Medicaid reimbursement under 10 medical indications and is the only Medicare-approved mobile mechanical compression system under HCPCS code E0683.

Clinically Proven Benefits: Increases venous blood flow by 64% within 2 minutes and by 88% after 50 minutes of use.
Enhanced Mobility: Lightweight (250g), discreet, and wireless, allowing patients to remain active during treatment.
FDA-Designated Durable Medical Equipment (DME): Designed for repeated use across multiple patients.

Major Purchase Orders Driving Market Expansion

Therma Bright continues to strengthen its market presence through key purchase agreements:

Valor Medical Solutions: Placed an initial order for 100 Venowave VW5 units following successful pilot trials. The purchase equates to a minimum of $81,955 USD in HCPCS code reimbursements ($117,952 CAD). Valor anticipates increasing its orders bi-weekly to meet growing demand.
DME Authority: Confirmed a major purchase order of 1,750 Venowave VW5 units, totaling $1.43 million USD ($2.05 million CAD) in reimbursements. This milestone further solidifies DME’s role as a Premier Distributor Partner for Therma Bright.

Market Outlook: Seizing a Growing Opportunity

The global compression therapy market, valued at $4.18 billion in 2024, is projected to grow to $6.72 billion by 2033, representing a CAGR of 7.3%. Therma Bright is well-positioned to capitalize on this expanding market through strategic partnerships, timely reimbursements, and the increasing adoption of Venowave VW5.

“With strong distributor commitments, rapid reimbursement processing, and increasing patient demand, we anticipate significant revenue growth in 2025 and beyond,” added Rob Fia.

Therma Bright remains committed to innovation, accessibility, and enhancing patient care as it scales its commercialization efforts for Venowave VW5 in the U.S. healthcare market.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by TBRIF to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Therma Bright Inc. (OTC: TBRIF) Expands in $6.72 Billion Compression Market

Board of Fire Commissioners, Fire District 3, Township of Old Bridge, Announces Opportunities for Firefighter Positions

The Board of Fire Commissioners, Fire District 3, Township of Old Bridge, has announced the availability of positions for individuals seeking careers in firefighting. These openings provide excellent opportunities for those interested in serving the community and contributing to public safety.

The Board of Fire Commissioners, Fire District 3, Township of Old Bridge, is dedicated to maintaining the highest fire protection and emergency response services standards. The district seeks qualified candidates for Firefighter Jobs in Old Bridge, including full-time and Part-Time Firefighter Jobs in Old Bridge. These positions are vital to ensuring the safety and well-being of residents within the district’s jurisdiction.

Individuals with a passion for public service and a commitment to upholding the values of safety and professionalism are encouraged to apply. The district provides comprehensive training, state-of-the-art equipment, and a supportive environment that fosters growth and development in the firefighting profession.

Applicants must meet the specified qualifications outlined by the Board of Fire Commissioners, Fire District 3, Township of Old Bridge. Detailed information about the application process and requirements can be accessed on the district’s official website. Interested candidates are encouraged to explore these rewarding opportunities by visiting the designated links for Firefighter Jobs in Old Bridge and Part-Time Firefighter Jobs in Old Bridge.

About Board of Fire Commissioners, Fire District 3, Township of Old Bridge:

The Board of Fire Commissioners, Fire District 3, Township of Old Bridge, remains committed to attracting skilled and dedicated professionals to join its team. These firefighter roles represent a chance to make a meaningful impact while pursuing a fulfilling career in public service.

Media Contact
Company Name: Board of Fire Commissioners, Fire District 3, Township of Old Bridge
Contact Person: Michael Sassi
Email: Send Email
Phone: (732) 723-1124
Address:913 Englishtown Rd
City: Old Bridge
State: NJ
Country: United States
Website: https://www.obfd3.com/

Pro Defense Pest Control Expands Comprehensive Pest Management Services in San Antonio

Pro Defense Pest Control, a trusted name in pest management, is pleased to announce an expansion of its comprehensive pest control solutions, designed to provide effective and eco-friendly pest management services for residential and commercial properties across the region.

Recognized as a leading Pest Control Company San Antonio, Pro Defense Pest Control employs advanced techniques and state-of-the-art equipment to address various pest issues, including ants, rodents, termites, and more. With a focus on delivering tailored solutions, the company ensures each property receives customized treatments to eliminate pests while preventing future infestations.

Pro Defense Pest Control’s team of highly trained professionals prioritizes safety and environmental sustainability in all pest management services. Using innovative methods and integrated pest management strategies, this Local Pest Control Company San Antonio provides services that are both effective and minimally invasive to homes and businesses.

Homeowners and business owners seeking reliable solutions can depend on Pro Defense Pest Control for its commitment to quality and customer satisfaction. By offering competitive pricing and flexible scheduling, this trusted provider ensures convenient access to expert pest management services.

For more information about pest management services in the area, visit Pro Defense Pest Control’s official website and learn why it is a preferred choice for Pest Control San Antonio.

About Pro Defense Pest Control:

Pro Defense Pest Control is a reputable pest control service provider specializing in innovative and eco-conscious solutions for pest management. Serving the greater San Antonio area, the company delivers reliable, effective, and affordable services to residential and commercial clients, ensuring long-term pest prevention and control.

Media Contact
Company Name: Pro Defense Pest Control – San Antonio
Contact Person: Kyle Weaver
Email: Send Email
Phone: (830) 267-2907
Address:12951 Huebner Rd #780371
City: San Antonio
State: TX 78230
Country: United States
Website: http://prodefensepestcontrol.com

Prime Heating & Cooling: Trusted Experts in HVAC Services in Smithfield, RI

Prime Heating & Cooling has established itself as a leading provider of reliable HVAC services in Smithfield, RI, offering expert heating, cooling, and maintenance solutions. With a team of highly skilled professionals, the company has earned a reputation for delivering superior service and ensuring customer satisfaction. Whether it’s a routine system check-up or an urgent repair, Prime Heating & Cooling is committed to providing timely and effective services.

Comprehensive Heating and Cooling Solutions

Prime Heating & Cooling specializes in a wide range of services, ensuring that residents in Smithfield can rely on the company for all their HVAC needs. The team can handle any situation, from heating to emergency AC repair with expertise and efficiency. The company is known for its quick response times and ability to address routine and emergency HVAC issues.

Heating Repair Services You Can Count On

As the colder months approach, a properly functioning heating system becomes essential for comfort and safety. Prime Heating & Cooling offers comprehensive heating repair Smithfield services designed to ensure that heating systems are operating at their best. Whether it’s a malfunctioning furnace or a broken thermostat, the experienced technicians at Prime Heating & Cooling can diagnose and repair the problem quickly, restoring warmth to homes in Smithfield.

Emergency AC Repair for Year-Round Comfort

In addition to heating services, Prime Heating & Cooling provides reliable emergency AC repair Smithfield for those hot summer days when air conditioning systems unexpectedly break down. The company’s emergency services are available 24/7, ensuring that residents don’t have to endure extreme temperatures for long. With a fast response time and the ability to handle all air conditioning unit makes and models, Prime Heating & Cooling is the go-to service provider for AC repairs in Smithfield.

Expert Heat Pump Maintenance Services

Prime Heating & Cooling also specializes in heat pump maintenance Smithfield, helping homeowners keep their systems running efficiently and effectively. Regular maintenance can extend a heat pump’s lifespan, improve energy efficiency, and prevent costly repairs. The company’s maintenance services include thorough inspections, cleaning, and performance checks to ensure that heat pumps work correctly throughout the year.

Commitment to Quality and Customer Satisfaction

Prime Heating & Cooling is committed to providing its customers with the highest level of service. The company prides itself on its professionalism, expertise, and attention to detail. Whether repairing a broken heating system or performing routine maintenance on an air conditioning unit, the Prime Heating & Cooling team is dedicated to ensuring that customers receive the best possible service. The company’s goal is to ensure that every client’s home stays comfortable, no matter the season.

About Prime Heating & Cooling

Prime Heating & Cooling is a full-service HVAC company based in Smithfield, RI. It specializes in heating, cooling, and maintenance services and is committed to providing reliable, high-quality solutions that meet the needs of area homeowners. With a focus on customer satisfaction and expert service, Prime Heating & Cooling is Smithfield’s trusted choice for HVAC services.

Media Contact
Company Name: Prime Heating & Cooling
Contact Person: Tyler Steiner
Email: Send Email
Phone: (401) 443-6769
Address:10C Appian Way
City: Smithfield
State: RI 02917
Country: United States
Website: https://getprimehvac.com/

Locksmith 4 You Expands Rapid Response Services in St. Louis

Locksmith 4 You, a trusted name in locksmith services, announces the expansion of its rapid response solutions across the St. Louis area. Known for its reliability and expertise, the company is committed to addressing the growing demand for professional locksmith services in both the residential and automotive sectors.

As the need for dependable locksmith services rises, Locksmith 4 You has enhanced its capabilities to ensure quick and efficient solutions. The company’s team of certified professionals specializes in a variety of services, including emergency lockouts, lock replacements, and advanced security installations. This expansion reinforces the company’s dedication to providing cutting-edge support tailored to the needs of the local community.

With a growing reputation as a leading locksmith in St. Louis, the company has become a go-to provider for both homeowners and businesses. Their expertise extends to advanced automotive locksmith services, such as key programming and ignition repairs. As an experienced automotive locksmith in St. Louis, the team ensures that vehicle owners can regain access quickly and safely.

The company also caters to individuals in need of a locksmith for a car in St. Louis by offering innovative solutions for lost or damaged keys. Whether addressing traditional locks or modern keyless entry systems, Locksmith 4 You is equipped to handle even the most complex automotive challenges.

With this strategic expansion, Locksmith 4 You aims to provide the residents and businesses of St. Louis with unparalleled service and security. For more information on their wide range of locksmith services, visit their website or contact their 24/7 customer support team.

About

Locksmith 4 You is a leading provider of locksmith solutions in St. Louis, offering comprehensive services for residential, commercial, and automotive needs. Dedicated to customer satisfaction and safety, the company delivers professional and reliable service tailored to the community’s unique demands.

Media Contact
Company Name: Locksmith 4 You
Contact Person: Mike
Email: Send Email
Phone: (314) 207-3993
Address:5340 Delmar Blvd
City: St. Louis
State: MO 63112
Country: United States
Website: locksmith4you.org/

Apéritif Restaurant Wins a Place in Indonesia’s Best by Travel + Leisure’s Tastemakers List

“Milk and Honey Dessert created by Apéritif Restaurant”

Apéritif Restaurant is thrilled to announce its inclusion in Travel + Leisure’s prestigious Tastemakers 2024 list, recognizing it as one of Indonesia’s finest dining establishments. This accolade celebrates Apéritif’s unwavering commitment to culinary excellence and innovation.

Ubud, Bali – January 29, 2025 – Nestled in the lush landscapes of Ubud, Apéritif offers guests a unique dining experience that seamlessly blends Indonesian flavors with international techniques. Under the visionary leadership of Executive Chef Nic Vanderbeeken, the restaurant presents an eclectic degustation menu that takes diners on a global culinary journey. Chef Nic’s progressive and eclectic cooking philosophy has been instrumental in crafting one-of-a-kind creations that delight the senses.

The restaurant’s interior transports guests back to the 1920s with its colonial-inspired décor, featuring black-and-white checkered floors, vintage chandeliers, and intricate baroque patterns. This elegant setting provides the perfect backdrop for Apéritif’s meticulously curated menus, which include options for vegan and vegetarian diners, as well as romantic candlelight dinners.

Apéritif’s inclusion in the Tastemakers 2024 list is a testament to its dedication to providing an unparalleled dining experience. The restaurant’s commitment to sustainability is evident through its use of locally sourced ingredients, many of which are grown on-site in their greenhouse. Additionally, Apéritif boasts an extensive wine cellar featuring over 180 of the world’s most exclusive wines, curated to complement each dish perfectly.

“We are deeply honored to be recognized by Travel + Leisure’s Tastemakers 2024,” said Chef Nic Vanderbeeken. “This accolade reflects the hard work and passion of our entire team, and our unwavering commitment to delivering exceptional culinary experiences to our guests.”

Apéritif invites guests to embark on a culinary journey that transcends borders, offering an experience that is both innovative and deeply rooted in Indonesia’s rich culinary traditions.

About Apéritif Restaurant

Located just north of Ubud, Bali, Apéritif Restaurant is part of the Viceroy Bali and offers a fine dining experience that combines global cuisine with Indonesian ingredients. Apéritif regularly partners with guest Michelin Star chefs to create one of a kind culinary creations. The restaurant features a seven-course degustation menu, a dedicated vegetarian menu, and an extensive wine cellar. Apéritif is committed to sustainability, utilizing locally sourced produce and implementing eco-friendly practices throughout its operations. You can visit this fine dining Ubud restaurant here.

For Reservations and Inquiries:

Apéritif Restaurant

Br. Nagi, Jl. Lanyahan, Petulu Kecamatan Ubud, Kabupaten Gianyar, Bali 80571, Indonesia

Phone: +62 361 908 2 777

Email: res@aperitif.com

Website: https://www.aperitif.com/

For media visit online-media-room

Contact: Ni N Suryantini (Surya)

Assistant Director of Communications

Media Contact
Company Name: Apéritif Restaurant
Contact Person: Patrick Farrell
Email: Send Email
Address:Br. Nagi, Jl. Lanyahan, Petulu Kecamatan Ubud, Kabupaten Gianyar
City: Ubud, 80571
State: Bali
Country: Indonesia
Website: https://www.aperitif.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Apéritif Restaurant Wins a Place in Indonesia’s Best by Travel + Leisure’s Tastemakers List

Asch Roofing Expands Services to Meet Growing Demand for New Roof Installations and Repairs in Local Area

Asch Roofing, a leading provider of roofing services, has announced the expansion of its offerings to serve better homeowners and businesses needing reliable roofing and gutter solutions. This move is in response to the region’s increasing demand for professional roofing services.

The company’s experienced roofing experts are dedicated to providing top-quality service, from routine roof repairs to complex gutter repair near-me projects. With years of industry experience, Asch Roofing has built a strong reputation for delivering superior craftsmanship and excellent customer care.

“We are committed to helping our community by ensuring that every roof is safe, secure, and built to last,” said a representative from Asch Roofing. “By expanding our services, we are making it easier for customers to access trusted, local experts for all their roofing and gutter needs.”

Asch Roofing’s approach covers a range of services, including roof repair company near me solutions, addressing issues such as leaks, weather damage, and wear and tear. Whether repairing shingles, replacing roof sections, or tackling gutter maintenance, the company is equipped to handle challenges efficiently. Additionally, Asch Roofing offers new roof installation near me, providing reliable, long-lasting ones. The company also includes slate roof installation, slate roof repair, skylight installation, and siding repair, meeting the diverse needs of property owners.

The company emphasizes the importance of regular roof inspections and maintenance, helping customers avoid costly repairs and ensuring properties remain in top condition. Asch Roofing’s commitment to transparency and customer satisfaction has earned it a reputation as one of the most trusted roofing contractors in the area. For further information or to request a quote, contact Asch Roofing today.

About Asch Roofing

Asch Roofing is a trusted company specializing in new roof installations, repairs, and gutter services for residential and commercial properties. Focusing on quality and customer satisfaction, it is committed to delivering dependable, long-lasting solutions for every roofing need.

Media Contact
Company Name: Asch Roofing
Contact Person: John Asch
Email: Send Email
Phone: (732) 238-9917
Address:10 Pierson St
City: Monmouth Junction
State: NJ
Country: United States
Website: https://www.aschroofing.com/